Exact Mass: 576.3046654
Exact Mass Matches: 576.3046654
Found 500 metabolites which its exact mass value is equals to given mass value 576.3046654
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Oleandrin
Oleandrin is a steroid saponin that consists of oleandrigenin having a 2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl residue attached to the oxygen function at position 3. It is a cardenolide glycoside, a 14beta-hydroxy steroid, a steroid ester and a steroid saponin. It is functionally related to an oleandrigenin. Oleandrin has been used in trials studying the treatment of Lung Cancer and Chemotherapeutic Agent Toxicity. Oleandrin is a natural product found in Daphnis nerii, Plumeria, and other organisms with data available. Oleandrin is a lipid soluble cardiac glycoside with potential antineoplastic activity. Upon administration, oleandrin specifically binds to and inhibits the alpha3 subunit of the Na/K-ATPase pump in human cancer cells. This may inhibit the phosphorylation of Akt, upregulate MAPK, inhibit NF-kb activation and inhibit FGF-2 export and may downregulate mTOR thereby inhibiting p70S6K and S6 protein expression. All of this may lead to an induction of apoptosis. As cancer cells with relatively higher expression of the alpha3 subunit and with limited expression of the alpha1 subunit are more sensitive to oleandrin, one may predict the tumor response to treatment with lipid-soluble cardiac glycosides such as oleandrin based on the tumors Na/K-ATPase pump protein subunit expression. Overexpression of the alpha3 subunit in tumor cells correlates with tumor proliferation. See also: Nerium oleander leaf (part of). A steroid saponin that consists of oleandrigenin having a 2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl residue attached to the oxygen function at position 3. D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2262 Oleandrin (PBI-05204) inhibits the Na+, K+-ATPase activity with an IC50 of 620 nM. Oleandrin (PBI-05204) inhibits the Na+, K+-ATPase activity with an IC50 of 620 nM.
Cerberin
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides A cardenolide glycoside that is the 2-acetyl derivative of neriifolin.
Anaerobilin
Etiopurpurin
Foliandrin
PA(8:0/18:1(12Z)-O(9S,10R))
PA(8:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(12Z)-O(9S,10R)/8:0)
PA(18:1(12Z)-O(9S,10R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/8:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/18:1(9Z)-O(12,13))
PA(8:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(9Z)-O(12,13)/8:0)
PA(18:1(9Z)-O(12,13)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/8:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Caseargrewiin C
A diterpenoid of the clerodane group isolated from the bark of Casearia grewiifolia and has been shown to exhibit antimalarial and antimycobacterial activity.
methyl-ent-15alpha-acetoxy-1alpha-(2-methyl-2,3-epoxybutyryloxy)-9alpha-hydroxy-7alpha-propionylyloxykaur-16-en-19-oate|methyl-ent-15alpha-acetoxy-1alpha-<2-methyl-2,3-epoxybutyryloxy>-9alpha-hydroxy-7alpha-propionylyloxykaur-16-en-19-oate
methyl-ent-1alpha7alpha-di<2-methyl-2,3-epoxybutyryloxy>-9alpha,15alpha-dihydroxykaur-16-en-19-oate|methyl-ent-1alpha7alpha-di[2-methyl-2,3-epoxybutyryloxy]-9alpha,15alpha-dihydroxykaur-16-en-19-oate
(1S,3aR,5S,6R,7S,7aR)-1-(1-acetoxyethyl)octahydro-4-methylidene-7-[(2S)-2-methyloxyran-2-yl]-6-[(3-methylpentanoyl)oxy]-2-oxo-1H-inden-5-yl (2E)-4-acetoxy-3-methylpent-2-enoate
rel-18(S),19(R)-diacetoxy-18,19-epoxy-6(R)-hydroxy-2(S)-(3xi-hydroxyoctanoyloxy)-5(R),8(S),9(S),10(R)-cleroda-3,13(16),14-triene
16alpha-[(6-O-sulfo-beta-D-glucopyranosyl)oxy]pregn-5-ene-3beta,20-diol
2alpha-hydroxyzuelanin-6beta-n-(3-hydroxy)octanoate
2,3-dihydro-3beta-methoxy-4beta-hydroxywithanolide E monoacetate
6-O-[(7Z,10Z)-hexadeca-7,10-dienoyl]-beta-D-fructofuranosyl-(2->1)-alpha-D-glucopyranoside
1-O-benzoylsalannic acid methyl ester|1-O-decinnamoyl-1-O-benzoylohchinin
cimicifugoside H-4|foetidinol-3-O-beta-D-xylopyranoside|foetidinol-3-O-beta-xyloside|neocimiside
C32H48O9_beta-D-Xylopyranoside, 3,17-dihydroxyspirosta-5,25(27)-dien-1-yl
C32H48O9_Card-20(22)-enolide, 16-(acetyloxy)-3-[(2,6-dideoxy-3-O-methylhexopyranosyl)oxy]-14-hydroxy-, (3beta,5beta,8xi,9xi,16beta)
Cys Ile Arg Trp
Cys Ile Trp Arg
Cys Leu Arg Trp
Cys Leu Trp Arg
Cys Arg Ile Trp
Cys Arg Leu Trp
Cys Arg Trp Ile
Cys Arg Trp Leu
Cys Trp Ile Arg
Cys Trp Leu Arg
Cys Trp Arg Ile
Cys Trp Arg Leu
Asp Met Arg Arg
Asp Arg Met Arg
Asp Arg Arg Met
Asp Arg Thr Trp
Asp Arg Trp Thr
Asp Thr Arg Trp
Asp Thr Trp Arg
Asp Trp Arg Thr
Asp Trp Thr Arg
Glu Arg Ser Trp
Glu Arg Trp Ser
Glu Ser Arg Trp
Glu Ser Trp Arg
Glu Trp Arg Ser
Glu Trp Ser Arg
Phe Lys Pro Trp
Phe Lys Trp Pro
Phe Pro Lys Trp
Phe Pro Gln Trp
C30H36N6O6 (576.2696195999999)
Phe Pro Trp Lys
Phe Pro Trp Gln
C30H36N6O6 (576.2696195999999)
Phe Gln Pro Trp
C30H36N6O6 (576.2696195999999)
Phe Gln Trp Pro
C30H36N6O6 (576.2696195999999)
Phe Trp Lys Pro
Phe Trp Pro Lys
Phe Trp Pro Gln
C30H36N6O6 (576.2696195999999)
Phe Trp Gln Pro
C30H36N6O6 (576.2696195999999)
His His Lys Arg
His His Gln Arg
His His Arg Lys
His His Arg Gln
His Lys His Arg
His Lys Arg His
His Gln His Arg
His Gln Arg His
His Arg His Lys
His Arg His Gln
His Arg Lys His
His Arg Gln His
Ile Cys Arg Trp
Ile Cys Trp Arg
Ile Lys Met Trp
Ile Lys Trp Met
Ile Met Lys Trp
Ile Met Gln Trp
Ile Met Trp Lys
Ile Met Trp Gln
Ile Gln Met Trp
Ile Gln Trp Met
Ile Arg Cys Trp
Ile Arg Trp Cys
Ile Trp Cys Arg
Ile Trp Lys Met
Ile Trp Met Lys
Ile Trp Met Gln
Ile Trp Gln Met
Ile Trp Arg Cys
Lys Phe Pro Trp
Lys Phe Trp Pro
Lys His His Arg
Lys His Arg His
Lys Ile Met Trp
Lys Ile Trp Met
Lys Leu Met Trp
Lys Leu Trp Met
Lys Met Ile Trp
Lys Met Leu Trp
Lys Met Trp Ile
Lys Met Trp Leu
Lys Pro Phe Trp
Lys Pro Trp Phe
Lys Arg His His
Lys Trp Phe Pro
Lys Trp Ile Met
Lys Trp Leu Met
Lys Trp Met Ile
Lys Trp Met Leu
Lys Trp Pro Phe
Leu Cys Arg Trp
Leu Cys Trp Arg
Leu Lys Met Trp
Leu Lys Trp Met
Leu Met Lys Trp
Leu Met Gln Trp
Leu Met Trp Lys
Leu Met Trp Gln
Leu Gln Met Trp
Leu Gln Trp Met
Leu Arg Cys Trp
Leu Arg Trp Cys
Leu Trp Cys Arg
Leu Trp Lys Met
Leu Trp Met Lys
Leu Trp Met Gln
Leu Trp Gln Met
Leu Trp Arg Cys
Met Asp Arg Arg
Met Ile Lys Trp
Met Ile Gln Trp
Met Ile Trp Lys
Met Ile Trp Gln
Met Lys Ile Trp
Met Lys Leu Trp
Met Lys Trp Ile
Met Lys Trp Leu
Met Leu Lys Trp
Met Leu Gln Trp
Met Leu Trp Lys
Met Leu Trp Gln
Met Gln Ile Trp
Met Gln Leu Trp
Met Gln Trp Ile
Met Gln Trp Leu
Met Arg Asp Arg
Met Arg Arg Asp
Met Trp Ile Lys
Met Trp Ile Gln
Met Trp Lys Ile
Met Trp Lys Leu
Met Trp Leu Lys
Met Trp Leu Gln
Met Trp Gln Ile
Met Trp Gln Leu
Pro Phe Lys Trp
Pro Phe Gln Trp
C30H36N6O6 (576.2696195999999)
Pro Phe Trp Lys
Pro Phe Trp Gln
C30H36N6O6 (576.2696195999999)
Pro Lys Phe Trp
Pro Lys Trp Phe
Pro Gln Phe Trp
C30H36N6O6 (576.2696195999999)
Pro Gln Trp Phe
C30H36N6O6 (576.2696195999999)
Pro Trp Phe Lys
Pro Trp Phe Gln
C30H36N6O6 (576.2696195999999)
Pro Trp Lys Phe
Pro Trp Gln Phe
C30H36N6O6 (576.2696195999999)
Gln Phe Pro Trp
C30H36N6O6 (576.2696195999999)
Gln Phe Trp Pro
C30H36N6O6 (576.2696195999999)
Gln His His Arg
Gln His Arg His
Gln Ile Met Trp
Gln Ile Trp Met
Gln Leu Met Trp
Gln Leu Trp Met
Gln Met Ile Trp
Gln Met Leu Trp
Gln Met Trp Ile
Gln Met Trp Leu
Gln Pro Phe Trp
C30H36N6O6 (576.2696195999999)
Gln Pro Trp Phe
C30H36N6O6 (576.2696195999999)
Gln Arg His His
Gln Trp Phe Pro
C30H36N6O6 (576.2696195999999)
Gln Trp Ile Met
Gln Trp Leu Met
Gln Trp Met Ile
Gln Trp Met Leu
Gln Trp Pro Phe
C30H36N6O6 (576.2696195999999)
Arg Cys Ile Trp
Arg Cys Leu Trp
Arg Cys Trp Ile
Arg Cys Trp Leu
Arg Asp Met Arg
Arg Asp Arg Met
Arg Asp Thr Trp
Arg Asp Trp Thr
Arg Glu Ser Trp
Arg Glu Trp Ser
Arg His His Lys
Arg His His Gln
Arg His Lys His
Arg His Gln His
Arg Ile Cys Trp
Arg Ile Trp Cys
Arg Lys His His
Arg Leu Cys Trp
Arg Leu Trp Cys
Arg Met Asp Arg
Arg Met Arg Asp
Arg Gln His His
Arg Arg Asp Met
Arg Arg Met Asp
Arg Ser Glu Trp
Arg Ser Trp Glu
Arg Thr Asp Trp
Arg Thr Trp Asp
Arg Trp Cys Ile
Arg Trp Cys Leu
Arg Trp Asp Thr
Arg Trp Glu Ser
Arg Trp Ile Cys
Arg Trp Leu Cys
Arg Trp Ser Glu
Arg Trp Thr Asp
Ser Glu Arg Trp
Ser Glu Trp Arg
Ser Arg Glu Trp
Ser Arg Trp Glu
Ser Val Trp Trp
C30H36N6O6 (576.2696195999999)
Ser Trp Glu Arg
Ser Trp Arg Glu
Ser Trp Val Trp
C30H36N6O6 (576.2696195999999)
Ser Trp Trp Val
C30H36N6O6 (576.2696195999999)
Thr Asp Arg Trp
Thr Asp Trp Arg
Thr Arg Asp Trp
Thr Arg Trp Asp
Thr Trp Asp Arg
Thr Trp Arg Asp
Val Ser Trp Trp
C30H36N6O6 (576.2696195999999)
Val Trp Ser Trp
C30H36N6O6 (576.2696195999999)
Val Trp Trp Ser
C30H36N6O6 (576.2696195999999)
Trp Cys Ile Arg
Trp Cys Leu Arg
Trp Cys Arg Ile
Trp Cys Arg Leu
Trp Asp Arg Thr
Trp Asp Thr Arg
Trp Glu Arg Ser
Trp Glu Ser Arg
Trp Phe Lys Pro
Trp Phe Pro Lys
Trp Phe Pro Gln
C30H36N6O6 (576.2696195999999)
Trp Phe Gln Pro
C30H36N6O6 (576.2696195999999)
Trp Ile Cys Arg
Trp Ile Lys Met
Trp Ile Met Lys
Trp Ile Met Gln
Trp Ile Gln Met
Trp Ile Arg Cys
Trp Lys Phe Pro
Trp Lys Ile Met
Trp Lys Leu Met
Trp Lys Met Ile
Trp Lys Met Leu
Trp Lys Pro Phe
Trp Leu Cys Arg
Trp Leu Lys Met
Trp Leu Met Lys
Trp Leu Met Gln
Trp Leu Gln Met
Trp Leu Arg Cys
Trp Met Ile Lys
Trp Met Ile Gln
Trp Met Lys Ile
Trp Met Lys Leu
Trp Met Leu Lys
Trp Met Leu Gln
Trp Met Gln Ile
Trp Met Gln Leu
Trp Pro Phe Lys
Trp Pro Phe Gln
C30H36N6O6 (576.2696195999999)
Trp Pro Lys Phe
Trp Pro Gln Phe
C30H36N6O6 (576.2696195999999)
Trp Gln Phe Pro
C30H36N6O6 (576.2696195999999)
Trp Gln Ile Met
Trp Gln Leu Met
Trp Gln Met Ile
Trp Gln Met Leu
Trp Gln Pro Phe
C30H36N6O6 (576.2696195999999)
Trp Arg Cys Ile
Trp Arg Cys Leu
Trp Arg Asp Thr
Trp Arg Glu Ser
Trp Arg Ile Cys
Trp Arg Leu Cys
Trp Arg Ser Glu
Trp Arg Thr Asp
Trp Ser Glu Arg
Trp Ser Arg Glu
Trp Ser Val Trp
C30H36N6O6 (576.2696195999999)
Trp Ser Trp Val
C30H36N6O6 (576.2696195999999)
Trp Thr Asp Arg
Trp Thr Arg Asp
Trp Val Ser Trp
C30H36N6O6 (576.2696195999999)
Trp Val Trp Ser
C30H36N6O6 (576.2696195999999)
Trp Trp Ser Val
C30H36N6O6 (576.2696195999999)
Trp Trp Val Ser
C30H36N6O6 (576.2696195999999)
3beta,15alpha,16alpha,24alpha-tetrahydroxy25,26,27-trinor-16,24-cyclo-cycloart-7-en-23-one-3-O-beta-D-xylopyranoside
POLY[4,4-METHYLENEBIS(PHENYL ISOCYANATE)-ALT-1,4-BUTANEDIOL/POLY(BUTYLENE ADIPATE)]
cyclooctane,(E)-5-hydroxy-2,2,6,6-tetramethylhept-4-en-3-one,ruthenium
C30H50O4Ru (576.2752300000001)
2,2-bis[4,4-cyclohexylidenebis(4-hydroxyphenyl)]propane
Albuterol sulfate
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
methyl 1-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-L-prolyl-beta-phenyl-L-phenylalaninate
[(2R,3R,4S,5R,6R)-2-[[(3S,4R,5R,8S,9S,10S,13R,14S,17R)-17-ethenyl-3-hydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-4-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] hydrogen sulfate
2,3-O-methyl-rhamnosyl tetracyclic spinosyn pseudoaglycone
(4Z,10Z,14E)-8,12-bis(2-carboxyethyl)-3,7,13,18-tetramethyl-1,2,17-trivinyl-23,24-dihydrobilin
3-[(21S,22S)-16-ethenyl-26-ethyl-4-hydroxy-12,17,21-trimethyl-11-(2-methylpropyl)-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
[(2R)-1-octanoyloxy-3-phosphonooxypropan-2-yl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
[(2R)-2-octanoyloxy-3-phosphonooxypropyl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
2-[[(2R)-3-acetyloxy-2-[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
3-ethyl-2-methoxy-5-methyl-6-[(1E,5E,7E,11E)-3,7,9,11-tetramethyl-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytrideca-1,5,7,11-tetraenyl]pyran-4-one
(5S,6R,9R)-5-methoxy-N-(2-methoxyphenyl)-3,6,9-trimethyl-2-oxo-14-(pyrazine-2-carbonylamino)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
C30H36N6O6 (576.2696195999999)